Publications

Toy M, Guler B, Somay K, Gencdal G, Yurdaydin C. Hepatitis Delta Infection in Turkey: A Meta-Analysis of Prevalence. IJID Regions 2024. [click here].

Ispas SA, Iliescu D, Ren L, So S, Toy M. Psychometric Tests for Hepatitis B- A Systematic Review. Evaluation & the Health Professions. 2023. [click here]. 

Pham TTH, Maria N, Cheng V, Nguyen B, Toy M, Hutton D, Conners EE, Nelson NP, Salomon JA, So S. Gaps in Prenatal Hepatitis B Screening and Management of HBsAg positive Pregnant Persons in the U.S., 2015-2020. Am J Prev Med. 2023 Mar 9:S0749-3797. [click here].

Pham TTH, Toy M, Hutton D, Thompson W, Conners EE, Nelson NP, Salomon JA, So S. Gaps and Disparities in Chronic Hepatitis B Monitoring and Treatment in the United States, 2016-2019. Med Care 2023 Apr 1;61(4):247-253. [click here].

Pham TTH, Nguyen TTL, So S, Hoang THV, Nguyen TTU, Ngo TB, Nguyen MP, Thai QH, Nguyen NK, Ho TQAL, Tran QP, Mai TS, Toy M, Pham MK. Knowledge and Attitude Related to Hepatitis C among Medical Students in the Oral Direct Acting Antiviral Agents Era in Vietnam. Int J Environ Res Public Health. 2022 Sep 28;19(19):12298. [click here].

 Toy M, Hutton D, Jia J, So S. Costs and Health Impact of Delayed Implementation of a National Hepatitis B Treatment Program in China. J Glob Health 2022 Jul 8;12:04043. [click here].

 Hutton DW, Toy M, Salomon JA, Conners EE, Nelson NP, Harris AM, So S. Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections. Sex Transm Dis. 2022 Jul 1;49(7):517-525. [click here]. 

Cohen C, Moraras K, Jackson M, Kamischke M, Gish RG, Brosgart CL, Toy M, Hutton D, Block TM, Wang S, So S. Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States. Hepatology. 2022 Apr;75(4):1062-1063. [click here].

Toy M, Hutton D, Harris A, Nelson N, Salomon J, So S. Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clin Infect Dis 2022 Jan 29;74(2):210-217. [click here].

Toy M, Hutton D, McCulloch K, Romero N, So SK, Cowie B. The Price Tag of a Potential Cure for Chronic Hepatitis B Infection: A Cost Threshold Analysis for USA, China, and Australia. Liver Int. 2022 Jan;42(1):16-25. [click here]. 

 Razavi, H, Blach S, Razavi-Shearer D…Toy M…, et. al. The Case for Simplifying and using Absolute Targets for Hepatitis Elimination Goals. J Viral Hepat. 2021 Jan;28(1):12-19. [click here].

Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, Scott N, Chhatwal J, Hall A. Cost-Effectiveness of Testing and Treatment for HBV and HCV Infections: An Analysis by Scenario, Region and Income. Value Health 2020 Dec;23(12):1552-1560. [click here].

Toy M, Ahiskali E, Yurdaydin C. Hepatitis Delta Virus Epidemiology in the Industrialized World. AIDS Rev. 2020 Oct 26;22(4):203-212. [click here]. 

Wang S, Toy M, Pham T, So S. Causes and Trends in Liver Disease and Hepatocellular Carcinoma among Men and Women who received Liver Transplants in the U.S., 2010-2019. PLoS One 2020 Sep 18;15(9):e0239393. [click here]. 

 Toy M, So S, Hutton DW. Hepatitis B cure: modeling the economics of a potential cost of a cure. Curr Opin HIV AIDS 2020 May;15(3):208-212. [click here].

Yurdaydin C, Toy M. Hepatitis Delta Virus Infection: A Large Burden After All? J Infect Dis. 2020 Apr 27;221(10):1573-1575. [click here]. 

Pham HTT, Le TX, Nguyen DT, Luu CM, Truong BD, Tran PD, Toy M, Bozkurt S, So S. Knowledge, attitudes and medical practice regarding hepatitis B prevention and management among healthcare workers in Northern Vietnam. PLoS One 2019 Oct 14;14(10):e0223733. [click here]. 

 Toy M, Hutton DW, Lauer J, Bulterys M, Hutin Y, So S. The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment. Lancet Gastroenterol Hepatol. 2019 Sep;4(9):668. [click here].

 Toy M, Hutton D, So S. Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment. Current Hepatology Reports 2019 Sep 15;18(6):357-362. [click here].

Tordrup D, Hutin Y, Stenberg K, Lauer J, Hutton D, Toy M, Scott N, Bulterys M, Ball A, Hirnschall G. Additional Resource needs for Viral Hepatitis Elimination through Universal Health Coverage: Projections in 67 Low-income and Middle-income Countries, 2016-2030. Lancet Glob Health. 2019 Sep;7(9):e1180-e1188. [click here]. 

Ispas S, So S, Toy M. Barriers to Disease Monitoring and Liver Cancer Surveillance among Patients with Chronic Hepatitis B in the United States. J Community Health. 2019 Jun;44(3):610-625. [click here].

 Pham HTT, Le TX, Nguyen DT, Luu CM, Truong BD, Tran PD, Toy M, So S. Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in Northern Vietnam. Plos One 2019 Apr 10;14(4):e0208154. [click here].

Toy M, Hutton DW, So S. Population Health and Economic Impact of Reaching the WHO Targets for Chronic Hepatitis B Diagnosis and Treatment in the United States. Health Aff (Millwood). 2018 Jul;37(7):1033-1040. [click here]. 

Toy M, Wei B, Virdi TS, Le A, Trinh H, Li J, Zhang J, Hsing AW, So SK, Nguyen MH. Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California. Hepatol Med Policy. 2018 Jun 5;3:6. [click here]. 

 Toy M.  The Public Health Impact and Cost-Effectiveness of Chronic Hepatitis B Diagnosis, Care and Treatment in the United States. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. National Academies 2017 Appendix 1. [click here].

Toy M, Hutton DW, So S. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015 Nov 4;10(11):e0139876. [click here].

Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv. 2015 Jan-Feb;33(1):178-90. [click here].

Shafiee H, Wang S, Inci F, Toy M, Henrich TJ, Kuritzkes DR, Demirci U. Emerging Technologies for Point-of-Care Management of HIV Infection. Annu Rev Med. 2015;66:387-405. doi: 10.1146/annurev-med-092112-143017. [click here].

Toy M. Cost-effective interventions in the control of chronic hepatitis B infection. EMJ Hepatol. 2014;1(1):71-76. [click here].

Toy M, Salomon JA, Hao J, Honglian G, Wang H, Wang J, Richardus JH, Xie Q. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. Hepatology 2014;60(1):46-55. [click here].

Toy M, Demirci U, So S. Preventing hepatocellular carcinoma: the crucial role of chronic hepatitis B monitoring and antiviral treatment. Hep Oncol. 2014 Jun;1(3):255-257. doi: 10.2217/hep.14.10. [click here].

Toy M. Cost-Effectiveness of Viral Hepatitis B & C Treatment. Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):973-85.  [click here].

Li S, Onder FO, Xie Q, Liu Y, Toy M. High disease progression and medical costs if not detected in a high endemic chronic hepatitis B region: a cost-effectiveness analysis. J Antivir Antiretrovir 2013;5:154-159. [click here].

Van Rosmalen J, Toy M, O’Mahony JF. A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete Event Simulation. Med Decis Making. 2013 Aug;33(6):767-79. [click here].

Chen S, Toy M, Yeh J, Wang J, Resch S. Cost-effectiveness of Adding Maternal Screening and Neonatal Immunoglobulin to Universal Hepatitis B Vaccination. Pediatrics 2013 Apr;131(4):e1135-43. [click here]. 

Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm SW, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle-income country. Eur J Health Econ. 2012 Oct;13(5):663-76. [click here]. 

Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen J, Richardus JH, Yurdaydin C. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011 Dec 12;11:337. [click here].

Veldhuijzen IK, Toy M, Hahne SJM, de Wit GE, Schalm SW, de Man RA, Richardus JH. Screening and early treatment of migrants for chronic hepatitis is cost-effective. Gastroenterology. 2010 Feb;138(2):522-30. [click here]. 

Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 2009;50(3):743-51. [click here]. 

Toy M, Veldhuijzen IK, Mostert MC, de Man RA, Richardus JH. Transmission routes of hepatitis B virus in chronic hepatitis B patients in the Netherlands. J Med Virol 2008 Mar;80(3):399-404. [click here].